Hospital Pharmacy最新文献

{"title":"Comment on \"Pharmacy Physiotherapy Interprofessional Education and Practice\".","authors":"Dr Richa Kashyap","doi":"10.1177/00185787261430820","DOIUrl":"https://doi.org/10.1177/00185787261430820","url":null,"abstract":"","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787261430820"},"PeriodicalIF":0.7,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13219108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148137853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real World Comparison of the Safety and Efficacy of Linezolid Versus Adjunctive Clindamycin for the Treatment of Necrotizing Skin and Soft Tissue Infections.","authors":"Kristen Salem, Yeji Lee, Kelvin Gandhi","doi":"10.1177/00185787261445895","DOIUrl":"https://doi.org/10.1177/00185787261445895","url":null,"abstract":"<p><strong>Purpose: </strong>Bacterial exotoxins play a crucial role in the pathogenicity of necrotizing skin and soft tissue infections (NSTI). Clindamycin has historically been utilized as an adjunctive antitoxin in empiric therapy along with broad-spectrum antibiotics, commonly vancomycin. However, due to toxicity concerns associated with this combination, and the similar mechanism of action, linezolid's role as a toxin suppressing agent has gained interest in recent years. The objective of this study was to assess the safety and efficacy of linezolid versus adjunctive clindamycin in the empiric treatment of NSTI.</p><p><strong>Methods: </strong>This multicenter retrospective cohort study included 144 adults admitted from April 2022 to December 2024 with a diagnosis of NSTI who received either linezolid or adjunctive clindamycin for at least 48 hours. The primary outcome was 30-day mortality. Secondary outcomes measured 60- and 90-day mortality, as well as hospital readmission, infection recurrence, and incidence of acute kidney injury (AKI), <i>Clostridioides difficile</i> infection (CDI), suspected serotonin syndrome, and new onset of thrombocytopenia.</p><p><strong>Results: </strong>There were no patients in the linezolid cohort that met the primary outcome (0% vs 4.4%; <i>P</i> = .12). The incidence of AKI was significantly higher among patients treated with adjunctive clindamycin (9.4% vs 33.0%; <i>P</i> = .001).</p><p><strong>Conclusion: </strong>There were no differences in mortality, hospital readmission, or infection recurrence between the linezolid and adjunctive clindamycin cohorts. The lower incidence of AKI observed in patients treated with linezolid suggests it may be considered a reasonable antitoxin alternative to adjunctive clindamycin in the empiric treatment of NSTI.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787261445895"},"PeriodicalIF":0.7,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13212419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148054141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Stability Assessment of Alternative Sugar-Free Pediatric Solution Containing Losartan Potassium.","authors":"Bruna S Bersagui, Gabriela A de Oliveira, Brendha L Camboim, Sílvia H O de Almeida, Márcio V Ayres, Cássia V Garcia","doi":"10.1177/00185787261444899","DOIUrl":"https://doi.org/10.1177/00185787261444899","url":null,"abstract":"<p><strong>Purpose: </strong>Losartan potassium is an antihypertensive drug commercialized only as tablets. As an alternative to the hospital pediatric extemporaneous preparations, it was developed a sugar-free oral liquid formulation containing this drug (2.0 mg/mL) in order to allow the dose adjustment, accuracy and easy administration.</p><p><strong>Methodology: </strong>The stability of formulation was evaluated at room temperature (15-30°C), refrigerated (2-8°C) and oven (40°C), during 56 days in amber glass bottles (n = 3). A stability-indicating analytical method by high performance liquid chromatography (HPLC) was used for drug determination weekly. The acceptance criterion was between 95.0% and 105.0%. Organoleptic characteristics, pH, viscosity, and microbiological content were also evaluated.</p><p><strong>Results: </strong>All samples under room and refrigerated conditions kept their pH values and microbiological content in accordance during all the period tested. However, for those at room temperature, the drug amount, formulation appearance and viscosity were adequate until the 42nd day of analysis, indicating that this was the recommended beyond-use date for the proposed solution.</p><p><strong>Conclusion: </strong>A simple and economical solution was obtained with the advantage to be sugar-free, without the cariogenic effect, and without the disadvantages of pharmaceutical suspensions, contributing to pediatric patients during hospital treatments.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787261444899"},"PeriodicalIF":0.7,"publicationDate":"2026-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13186917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147987264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypotensive Events Associated With PDE-5 Inhibitors in Pulmonary Arterial Hypertension: Assessment of the USFDA Adverse Event Reporting System Using Disproportionality and Interaction Analysis.","authors":"Kannan Sridharan, Gowri Sivaramakrishnan","doi":"10.1177/00185787261445857","DOIUrl":"https://doi.org/10.1177/00185787261445857","url":null,"abstract":"<p><strong>Background: </strong>Phosphodiesterase-5 inhibitors (PDE-5is) are fundamental in pulmonary arterial hypertension (PAH) treatment, often used in combination with other therapeutic agents. However, hypotension signals associated with these combinations remain inadequately characterized. We analyzed the United States Food and Drug Administration Adverse Event Reporting System (FAERS) to evaluate disproportionate signals of hypotension associated with PDE-5is alone and in combination therapy.</p><p><strong>Methods: </strong>We conducted a pharmacovigilance analysis of FAERS data from 2004 to 2024, employing both frequentist (reporting odds ratio, proportional reporting ratio) and Bayesian (information component, empirical Bayes geometric mean) approaches. Interaction signal scores (INTSS) were calculated to assess potential drug interactions between PDE-5is and other PAH therapies. Clinical outcomes were evaluated for both monotherapy and combination regimens.</p><p><strong>Results: </strong>Among 29 163 222 reports analyzed, 704 cases of PDE-5i-associated hypotension were identified (533 monotherapy, 171 combination therapy). While PDE-5i monotherapy showed no significant hypotension signals, combinations with endothelin antagonists (particularly bosentan) and prostacyclin analogs (notably epoprostenol) generated strong safety signals. Significant INTSS were detected for sildenafil and tadalafil with endothelin antagonists. Paradoxically, despite fewer hypotension reports, PDE-5i monotherapy was associated with higher rates of death and life-threatening events compared to combination therapy (<i>P</i> = .02).</p><p><strong>Conclusion: </strong>This analysis reveals significant hypotension signals with specific PDE-5i combinations in PAH treatment, particularly with endothelin antagonists and prostacyclin analogs. While combination therapy showed a higher frequency of hypotensive events, these episodes appeared more manageable than those occurring with monotherapy. These findings emphasize the need for careful monitoring and individualized risk assessment in PAH patients receiving PDE-5i-based therapy.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787261445857"},"PeriodicalIF":0.7,"publicationDate":"2026-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13187856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147987282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Associated with Multiple Drug Hypersensitivity Confirmed by Skin Testing.","authors":"Myriam Agrebi, Dhouha Sahnoun, Nadia Ghariani, Wessim Kermani, Chaker Ben Salem","doi":"10.1177/00185787261444898","DOIUrl":"https://doi.org/10.1177/00185787261444898","url":null,"abstract":"","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787261444898"},"PeriodicalIF":0.7,"publicationDate":"2026-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13157461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147874136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Implementation of a Clinical Decision Support System for Managing Drug-Disease Interactions in Outpatients with Cardiovascular and Diabetic Comorbidities: An Interventional Study at a Tertiary Hospital in Vietnam.","authors":"Hanh T H Nguyen, Thu Ha Vu, Ngoc Mai Vu Thi, Trong Hieu Le, Thu Huong Hoang Thi, Loan Tran Thi, Khanh Linh Doan Thi, Tuan Hieu Pham, Hai Le Ba, Thanh Hai Nguyen","doi":"10.1177/00185787261442157","DOIUrl":"https://doi.org/10.1177/00185787261442157","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the effectiveness of a combined intervention consisting of a clinical decision support system (CDSS) integrated into the hospital information system (HIS) and pharmacist consultation in managing drug-disease interactions (DDSIs) among outpatients with cardiovascular disease (CVD) and diabetes mellitus (DM) comorbidities at a Tertiary Hospital in Vietnam.</p><p><strong>Methods: </strong>A pre- and post-interventional study was conducted using data from outpatient prescriptions and electronic medical records. The pre-intervention phase took place from May 1 to August 31, 2024, followed by the post-intervention phase from September 15, 2024, to January 15, 2025. Following the CDSS implementation in September 2024, clinical pharmacists performed interventions, which were prospectively documented. Descriptive statistics and comparative tests were used for data analysis.</p><p><strong>Results: </strong>Patient characteristics were comparable between two phases, with a mean age of 76 ± 8.5 years (pre-intervention phase) and 77 ± 7.5 years (post-intervention phase). After the intervention, the prevalence of absolute contraindication showed a statistically significant decrease (<i>P</i> < 0.05). The rate of relative contraindication plummeted from 0.33% to 0.01% (<i>P</i> < 0.05). Notably, relative contraindications involving bisoprolol - chronic obstructive pulmonary diseases and gliclazide-hepatic fibrosis - cirrhosis sharply reduced post-intervention (<i>P</i> < 0.001). \"Use with caution\" interactions also witnessed a decline from 0.20% to 0.13% (<i>P</i> < 0.05), most significantly for lisinopril/hydrochlorothiazide - gout (<i>P</i> < 0.001). Pharmacist interventions were largely fully accepted, except for a few gout-related cases that received partial acceptance. No interventions were rejected.</p><p><strong>Conclusions: </strong>The integration of CDSS into HIS and pharmacist interventions were associated with significantly reduced harmful DDSIs in high-risk CV-DM patients. This approach demonstrates the value of integrated clinical tools and multidisciplinary collaboration in optimizing medication safety in outpatient settings.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787261442157"},"PeriodicalIF":0.7,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13132978/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ibuprofen-Induced Pemphigus Vulgaris: A Case Report.","authors":"Pongpan Chaiyapak, Tippawan Siritientong","doi":"10.1177/00185787261435480","DOIUrl":"10.1177/00185787261435480","url":null,"abstract":"<p><p>Pemphigus Vulgaris (PV) is a chronic autoimmune blistering disease. Although pharmacological agents, particularly those containing thiol groups, have been identified as precipitating factors, reports of non-thiol drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs), causing PV remain limited. We report a case of a 41-year-old Myanmar female who developed generalized bullous eruptions, oral ulcers, and ocular pain after the concurrent use of ibuprofen and penicillin V. She presented with extensive cutaneous erosions complicated by sepsis and malnutrition. Although penicillin V was initially suspected, a causality assessment performed by a pharmacist using the Naranjo algorithm identified ibuprofen as the \"probable\" culprit of the reaction. This assessment is crucial for guiding subsequent therapeutic decisions. The patient was successfully managed with systemic corticosteroids, nutritional support, and antibiotics. Importantly, the exclusion of penicillin allergy allowed the use of piperacillin/tazobactam to effectively treat sepsis. This rare case of ibuprofen-induced PV highlights the critical role of pharmacists in performing adverse drug reaction assessments to accurately identify the causative agent, thereby enabling safe and effective therapeutic decision-making.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787261435480"},"PeriodicalIF":0.9,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13110249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Optimization of Automated Dispensing Cabinet Profiling on Override Rates in the Emergency Department.","authors":"Jonathan Martinez Gines, Erika Dittmar, Tom Wolfel, Shivana Syne, Estela Trimino","doi":"10.1177/00185787261437404","DOIUrl":"10.1177/00185787261437404","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Automated dispensing cabinets (ADCs) are widely used in emergency departments (EDs) to enable rapid access to medications. However, use of the override function, which bypasses pharmacist review, has been associated with medication errors and adverse drug events. This quality improvement initiative aimed to reduce unnecessary ADC overrides through implementation of ADC profiling and workflow optimization strategies while maintaining timely medication access in a high-acuity emergency department.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This retrospective, single-site, pre-post intervention quality improvement study was conducted at a 950-bed community hospital with a high-volume adult ED. The intervention consisted of a coordinated strategy implemented sequentially and included standardization of the ED ADC formulary, development of a harmonized override medication list limited to time-sensitive therapies, redesign of the electronic health record ordering interface to align with ADC inventory and clinical protocols, and multidisciplinary staff education. Data was collected during a 5-month pre-implementation period from September 2024 through January 2025 and a 3-month post-implementation period from February 2025 through April 2025. The primary outcome was the monthly override rate per ADC. Secondary outcomes included identification of frequently overridden medications and evaluation of medication workflow timing metrics.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Emergency department override rates declined substantially following implementation. Monthly ED override rates decreased from a pre-intervention range of 12.21% to 16.35% to 1.65% in February 2025, 1.10% in March, and 0.90% in April. Cabinet-level override rates remained below the institutional benchmark of 3%, ranging from 1.2% to 6.8% (median 2.3%) during the first month post-implementation and subsequently 0.3% to 2.2% (median 1.2%) in March and 0.2% to 1.3% (median 0.9%) in April. Overrides involving high-risk medications, including opioids and anxiolytics, declined markedly following implementation. The mean time from medication order entry to pharmacist verification increased modestly from 11 to 13 minutes, and the mean time from pharmacist verification to medication removal increased from 52 to 55 minutes. Review of internal safety reporting systems and operational feedback did not identify medication delays or adverse events attributable to ADC profiling.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Implementation of ADC profiling supported by formulary standardization, override governance, EHR workflow alignment, and multidisciplinary education significantly reduced override rates in a high-acuity emergency department. These findings demonstrate that pharmacist verification and override restrictions can be integrated into ED medication workflows without compromising timely medication access and provide a practical framework for improving medication-use safety processes in e","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787261437404"},"PeriodicalIF":0.9,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13109246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug-Related Problems in Outpatient Prescriptions Across Different Levels of Care in Vietnam: A Multicentre Cross-Sectional Study in a Resource-Constrained Health System.","authors":"Thang Nguyen, Vy Thao Tran, Ly Truong Cam Nguyen, Suol Thanh Pham, Khanh Duy Dang","doi":"10.1177/00185787261435507","DOIUrl":"10.1177/00185787261435507","url":null,"abstract":"<p><strong>Background: </strong>Drug-related problems (DRPs) are a common and largely preventable cause of medication-related harm in outpatient care. The risk is amplified in resource-constrained health systems, where high prescribing workload and limited clinical pharmacy capacity may compromise prescribing quality and medication use. Evidence on the burden and determinants of DRPs across different levels of care remains limited in many low- and middle-income countries, including Vietnam.</p><p><strong>Objectives: </strong>To estimate the prevalence and types of DRPs in outpatient health insurance prescriptions and to identify factors associated with DRP occurrence across facilities at different levels of care in Vietnam.</p><p><strong>Methods: </strong>A multicentre cross-sectional study was conducted using 969 adult outpatient health insurance prescriptions issued between 2023 and 2024 at one provincial general hospital and two district-level health centres. Prescriptions were systematically sampled and retrospectively assessed for DRPs using the national framework issued by the Vietnamese Ministry of Health, which is aligned with Pharmaceutical Care Network Europe concepts. DRPs were categorised into drug selection-related problems and dose- or administration-related problems. Multivariable logistic regression analysis was performed to examine patient-, prescription-, and facility-level factors associated with the presence of at least one DRP.</p><p><strong>Results: </strong>DRPs were identified in 612 prescriptions (63.2%). Dose- and administration-related problems predominated, with inappropriate timing of administration being the most frequent issue (52.5%). Prescriptions containing five or more medicines were significantly more likely to include DRPs than those with fewer medicines (adjusted odds ratio [aOR] 3.41; 95% confidence interval [CI] 2.46-4.72). Digestive system disease diagnoses were strongly associated with DRPs compared with cardiovascular diseases (aOR 11.96; 95% CI 5.27-27.14). Substantial facility-level variation was observed, with one district-level site showing markedly higher odds of DRPs than the provincial hospital (aOR 8.24; 95% CI 4.97-13.64).</p><p><strong>Conclusions: </strong>DRPs were highly prevalent in outpatient prescriptions and were largely driven by preventable dosing and administration issues. The pronounced variation across levels of care highlights inequities in outpatient medication safety and underscores the need for targeted, practice-oriented medication safety strategies and strengthened clinical pharmacy services, particularly in lower-resource district-level settings.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787261435507"},"PeriodicalIF":0.9,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13099739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of Glyburide Use During Pregnancy: A Real-World Study Based on the FAERS Database.","authors":"Xianyan Yan, Hunong Xiang, Jingzhong Ou, Li Pan, Xiaoyan Wang, Liping Liu, Yuanling Zhou, Yan Li, Ronghua Zhang, Yanping Wu","doi":"10.1177/00185787261433433","DOIUrl":"10.1177/00185787261433433","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the adverse event profile and potential safety signals associated with glyburide use during pregnancy using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).</p><p><strong>Methods: </strong>Data from FAERS (Q1 2015-Q1 2025) were analyzed. Pregnant cases and glyburide exposures were identified using standardized MedDRA terminology. Signal detection was conducted using the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS) algorithms.</p><p><strong>Results: </strong>A total of 284 712 pregnant women were included, among whom 164 used glyburide. Seventeen positive safety signals were detected. Hypoglycaemia neonatal, congenital anomaly in offspring, and maternal hypoglycaemia were consistent with drug labeling and previous reports. Additional newly identified signals included caesarean section, placenta praevia, amniotic fluid volume decreased, blood creatinine increased, hypoxia, metabolic acidosis, umbilical cord abnormality, and others. At the system organ class (SOC) level, positive signals were observed for metabolism and nutrition disorders, endocrine disorders, and pregnancy, puerperium and perinatal conditions.</p><p><strong>Conclusion: </strong>This real-world FAERS-based analysis suggests that glyburide use during pregnancy may be associated with various adverse metabolic and pregnancy-related outcomes. Caution is warranted when prescribing glyburide for patients with HIP, with particular attention to monitoring placental function and neonatal glucose levels. Further prospective studies are needed to validate these findings.</p>","PeriodicalId":13002,"journal":{"name":"Hospital Pharmacy","volume":" ","pages":"00185787261433433"},"PeriodicalIF":0.9,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13090241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147722641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}